\-\ Texto\\:\\ \ \(0\)\
\-\ disoriented\\ x\\ 3\ \(1\)\
\-\ supportive\\ with\\ medrol\\ dose\\ pack\\ and\\ dilantin\ \(0\)\
\-\ \\â\\€\\¢\\ abnormal\\ high\\ signal\\ intensity\\ on\\ t2\\ and\\ flair\\ sequences\\ in\\ the\\ posterior\\ temporal\\ and\\ occipital\\ lobes\\ on\\ the\\ left\\.\ \(0\)\
\-\ \\â\\€\\¢\\ abnormal\\ leptomeningeal\\ enhancement\\ in\\ same\\ location\\ following\\ contrast\\ administration\\.\ \(0\)\
\-\ cns\\ vasculitis\ \(0\)\
\-\ \\â\\€\\¢\\ meningtitis\\/encephalitis\ \(0\)\
\-\ \\â\\€\\¢\\ lymphoma\ \(6\)\
\-\ \\â\\€\\¢\\ leptomeningeal\\ tumor\\ spread\ \(0\)\
\-\ \\â\\€\\¢\\ vasculitis\ \(1\)\
\-\ 55\\ year\\ old\\ alcoholic\\ woman\\ was\\ admitted\\ to\\ hospital\\ with\\ confusion\\ and\\ delirium\\.\\ \\ preliminary\\ diagnosis\\ was\\ wernicke\\ encephalopathy\ \(0\)\
\-\ pathology\\ report\\ on\\ brain\\ biopsy\\ is\\ as\\ follows\\:\ \(0\)\
\-\ localized\\ cortical\\ vascular\\ abnormalities\\ \\(cannot\\ exclude\\ vasculitis\\)\\ \\ associated\\ selective\\ neuronal\\ necrosis\\ and\\ minor\\ phagocytic\\ reaction\\ \\ \ \(0\)\
\-\ no\\ evidence\\ of\\ meningeal\\ infiltration\\,\\ neoplasm\\,\\ granulomatous\\ reaction\\,\\ viral\\ \\ cytopathologic\\ effects\\,\\ or\\ acute\\ inflammation\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ vasculitis\\:\\ 0\\.3165621282359259\ \(0\)\
\-\ leptomeningeal\\:\\ 0\\.24044593479354215\ \(0\)\
\-\ reaction\\:\\ 0\\.19345863907500435\ \(0\)\
\-\ delirium\\:\\ 0\\.1737534819612287\ \(0\)\
\-\ phagocytic\\:\\ 0\\.1737534819612287\ \(0\)\
\-\ cytopathologic\\:\\ 0\\.16801923290057502\ \(0\)\
\-\ medrol\\:\\ 0\\.16357140377931864\ \(0\)\
\-\ wernicke\\:\\ 0\\.15686464033612696\ \(0\)\
\-\ dilantin\\:\\ 0\\.1497551845928179\ \(0\)\
\-\ preliminary\\:\\ 0\\.1497551845928179\ \(0\)\
\-\ alcoholic\\:\\ 0\\.1430484211496262\ \(0\)\
\-\ disoriented\\:\\ 0\\.13917838874218474\ \(0\)\
\-\ neuronal\\:\\ 0\\.13917838874218474\ \(0\)\
\-\ abnormal\\:\\ 0\\.13662218062095446\ \(0\)\
\-\ selective\\:\\ 0\\.1349664510237791\ \(0\)\
\-\ meningeal\\:\\ 0\\.12785699528047004\ \(0\)\
\-\ confusion\\:\\ 0\\.12163055847469663\ \(0\)\
\-\ encephalopathy\\:\\ 0\\.11977502515462293\ \(0\)\
\-\ pack\\:\\ 0\\.11807760939867737\ \(0\)\
\-\ effects\\:\\ 0\\.11807760939867737\ \(0\)\
\-\ and\\:\\ 0\\.11747640723218468\ \(0\)\
\-\ infiltration\\:\\ 0\\.11214099727092397\ \(0\)\
\-\ follows\\:\\ 0\\.11125495847262894\ \(0\)\
\-\ exclude\\:\\ 0\\.10986050254569218\ \(0\)\
\-\ minor\\:\\ 0\\.10686498887212788\ \(0\)\
\-\ dose\\:\\ 0\\.10618151879799426\ \(0\)\
\-\ cns\\:\\ 0\\.10618151879799426\ \(0\)\
\-\ viral\\:\\ 0\\.10488110616521494\ \(0\)\
\-\ on\\:\\ 0\\.10302054747906816\ \(0\)\
\-\ spread\\:\\ 0\\.10214095314781994\ \(0\)\
\-\ localized\\:\\ 0\\.10214095314781994\ \(0\)\
\-\ granulomatous\\:\\ 0\\.10107288029071887\ \(0\)\
\-\ 55\\:\\ 0\\.09772973118268248\ \(0\)\
\-\ occipital\\:\\ 0\\.09729482103704579\ \(0\)\
\-\ flair\\:\\ 0\\.09672931953750218\ \(0\)\
\-\ report\\:\\ 0\\.09577672778621212\ \(0\)\
\-\ supportive\\:\\ 0\\.09499495735595681\ \(0\)\
\-\ lobes\\:\\ 0\\.09486759212449357\ \(0\)\
\-\ admitted\\:\\ 0\\.09316499503477715\ \(0\)\
\-\ inflammation\\:\\ 0\\.09138212323838077\ \(0\)\
\-\ sequences\\:\\ 0\\.09096025371532512\ \(0\)\
\-\ administration\\:\\ 0\\.09054712823470039\ \(0\)\
\-\ same\\:\\ 0\\.08994306410100121\ \(0\)\
\-\ pathology\\:\\ 0\\.08926070829530315\ \(0\)\
\-\ temporal\\:\\ 0\\.08734351348958219\ \(0\)\
\-\ necrosis\\:\\ 0\\.08691298723010972\ \(0\)\
\-\ hospital\\:\\ 0\\.08398692862026452\ \(0\)\
\-\ abnormalities\\:\\ 0\\.08236320089982876\ \(0\)\
\-\ cortical\\:\\ 0\\.0816310367859859\ \(0\)\
\-\ intensity\\:\\ 0\\.08073647553723501\ \(0\)\
\-\ biopsy\\:\\ 0\\.0797015742777761\ \(0\)\
\-\ was\\:\\ 0\\.07925306890064052\ \(0\)\
\-\ location\\:\\ 0\\.07917469097837102\ \(0\)\
\-\ neoplasm\\:\\ 0\\.0776192711276797\ \(0\)\
\-\ vascular\\:\\ 0\\.07506480923098813\ \(0\)\
\-\ brain\\:\\ 0\\.07088199471885977\ \(0\)\
\-\ following\\:\\ 0\\.06821084236620564\ \(0\)\
\-\ lymphoma\\:\\ 0\\.06771702873170089\ \(0\)\
\-\ enhancement\\:\\ 0\\.06544532417723434\ \(0\)\
\-\ t2\\:\\ 0\\.06541633131262563\ \(0\)\
\-\ high\\:\\ 0\\.06462119377049959\ \(0\)\
\-\ evidence\\:\\ 0\\.06453785180558011\ \(0\)\
\-\ signal\\:\\ 0\\.06445485685886841\ \(0\)\
\-\ acute\\:\\ 0\\.06150884121927463\ \(0\)\
\-\ associated\\:\\ 0\\.05992987633560683\ \(0\)\
\-\ tumor\\:\\ 0\\.05947313577466469\ \(0\)\
\-\ woman\\:\\ 0\\.05921676451178543\ \(0\)\
\-\ diagnosis\\:\\ 0\\.05894270024523289\ \(0\)\
\-\ posterior\\:\\ 0\\.058796673285129844\ \(0\)\
\-\ in\\:\\ 0\\.05657110867736918\ \(0\)\
\-\ contrast\\:\\ 0\\.05524584521647654\ \(0\)\
\-\ as\\:\\ 0\\.04567843044983609\ \(0\)\
\-\ the\\:\\ 0\\.0453756376314034\ \(0\)\
\-\ with\\:\\ 0\\.044528840299516134\ \(0\)\
\-\ or\\:\\ 0\\.039555162455171135\ \(0\)\
\-\ left\\:\\ 0\\.03878648823998788\ \(0\)\
\-\ no\\:\\ 0\\.036974840848308814\ \(0\)\
\-\ year\\:\\ 0\\.035040949257173604\ \(0\)\
\-\ old\\:\\ 0\\.03365144101249028\ \(0\)\
\-\ is\\:\\ 0\\.031138270871848832\ \(0\)\
\-\ to\\:\\ 0\\.028425464415667345\ \(0\)\
\-\ of\\:\\ 0\\.0222511251078083\ \(0\)\
\-\ can\\:\\ 0\\.0\ \(0\)\
\-\ not\\:\\ 0\\.0\ \(0\)\
